Wilex Ag

wilex is a biopharmaceutical company based in munich and is listed at the frankfurt stock exchange at the regulated market / prime standard. the company was founded in 1997 by a team of physicians and oncologists from the technical university of munich. focused on oncology, the company has a portfolio of near-to-market diagnostic and therapeutic products for the specific detection and targeted treatment of the clear cell renal cell carcinoma. the company’s product candidates redectane and rencarex are based on the antibody girentuximab . both product candidates completed a first phase iii trial and are ready to partner for further clinical development. furthermore the company offers via its subsidiary heidelberg pharma gmbh an attractive and highly promising antibody drug conjugate technology platform which is partnered with roche for selected antibodies and targets. the proprietary adc technology is based on the toxin amanitin, the most potent rna-polymerase ii inhibitor. heidelberg p